Tempus AI (NASDAQ:TEM) CFO Sells $634,095.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 11,529 shares of Tempus AI stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the transaction, the chief financial officer directly owned 114,866 shares in the company, valued at approximately $6,317,630. The trade was a 9.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James William Rogers also recently made the following trade(s):

• On Tuesday, May 19th, James William Rogers sold 10,853 shares of Tempus AI stock. The stock was sold at an average price of $44.07, for a total transaction of $478,291.71.

Tempus AI Trading Down 2.2%

NASDAQ:TEM opened at $60.27 on Friday. The stock has a market capitalization of $10.82 billion, a price-to-earnings ratio of -35.04 and a beta of 3.46. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96. The firm has a 50 day moving average of $50.38 and a 200 day moving average of $54.52.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same period in the previous year, the company earned ($0.24) earnings per share. The business’s revenue for the quarter was up 36.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

TEM has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research report on Monday, June 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. Guggenheim dropped their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a report on Tuesday. Nine investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $68.54.

Institutional Trading of Tempus AI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. GC Wealth Management RIA LLC purchased a new stake in Tempus AI in the fourth quarter valued at approximately $399,267,000. Voloridge Investment Management LLC raised its position in Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after buying an additional 1,039,176 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Tempus AI by 312.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock valued at $102,869,000 after acquiring an additional 965,730 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Tempus AI in the 2nd quarter valued at $54,020,000. Finally, Amova Asset Management Americas Inc. boosted its holdings in shares of Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.